Pharvaris NV Stock Quote PHVS - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

22.68

Bid

9.08

Ask

36.28

Volume

0.00 Day's Range 0.00

7.93 52 Week Range 33.00

Market Cap

925.864M

Previous Close

22.68

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

78,358

Shares Outstanding

40,822,916

Dividend Yield

PE Ratio

-9.18

Earnings Per Share (EPS)

-2.47

Revenue

Net Profit

-100.88M

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.pharvaris.com

Headquarters

Leiden, South Holland, Nld

Founded

1970

Pharvaris NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHVS. The last closing price for Pharvaris NV was $22.68. Over the last year, Pharvaris NV shares have traded in a share price range of $ 7.93 to $ 33.00.

Pharvaris NV currently has 40,822,916 shares outstanding. The market capitalization of Pharvaris NV is $925.86 million. Pharvaris NV has a price to earnings ratio (PE ratio) of -9.18.

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and...

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and...

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.57	-2.45161290323	23.25	25.5	21.875	74567	23.7742133	CS
4	-0.07	-0.307692307692	22.75	25.5	17.57	88724	21.7663257	CS
12	-5.32	-19	28	28.845	17.57	78358	23.50923343	CS
26	5.77	34.1218214075	16.91	33	15	123916	25.13699805	CS
52	13.29	141.533546326	9.39	33	7.93	84895	22.94446454	CS
156	-1.88	-7.65472312704	24.56	33	1.77	217198	12.15177242	CS
260	-2.32	-9.28	25	42.86	1.77	209304	12.9239145	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NUWENewellis Inc	$ 0.2783 (62.75%)	11.06M
AIREreAlpha Tech Corporation	$ 1.28 (49.45%)	7.44M
CMNDClearmind Medicine Inc	$ 1.70 (45.30%)	20.41M
SELFGlobal Self Storage Inc	$ 5.53 (32.61%)	171.63k
MTCMMTec Inc	$ 3.05 (32.61%)	3.93M
GPGreenPower Motor Company Inc	$ 1.20 (-34.07%)	178.11k
AGRIAgriFORCE Growing Systems Ltd	$ 0.099 (-31.44%)	951.54k
LICNLichen China Limited	$ 0.83 (-20.19%)	167.04k
PLTNPlutoniam Acquisition Corporation	$ 7.77 (-18.64%)	20.18k
NUVOHoldco Nuvo Group DG Ltd	$ 4.28 (-18.48%)	126.95k
FFIEFaraday Future Intelligent Electric Inc	$ 0.0485 (17.43%)	35.45M
CMNDClearmind Medicine Inc	$ 1.70 (45.30%)	20.41M
NUWENewellis Inc	$ 0.2783 (62.75%)	11.06M
ESPREsperion Therapeutics Inc	$ 2.35 (10.85%)	10.49M
NKLANikola Corporation	$ 0.6217 (-2.46%)	7.47M